Journal of Cataract & Refractive Surgery
Volume 30, Issue 1 , Pages 110-114, January 2004

Outcomes of laser in situ keratomileusis in patients with pigment dispersion syndrome☆☆☆

  • Nada S Jabbur, MD

      Affiliations

    • Refractive Surgery Service, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    • ,
  • Suhas Tuli, MD

      Affiliations

    • Refractive Surgery Service, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    • ,
  • Irina S Barequet, MD

      Affiliations

    • Geldschleger Eye Institute, Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Herzliya, Israel
    • Refractive Surgery Center, Herzliya Medical Center, Herzliya, Israel
    • ,
  • Terrence P O'Brien, MD

      Affiliations

    • Corresponding Author InformationReprint requests to Terrence P. O'Brien, MD, The Wilmer Eye Institute at Green Spring Station, 10753 Falls Road, Suite 455, Baltimore, Maryland 21093, USA.
    • Refractive Surgery Service, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Accepted 8 March 2003.

Abstract 

Purpose: To analyze the outcome of laser in situ keratomileusis (LASIK) in patients with pigment dispersion syndrome (PDS).

Setting: Outpatient ambulatory laser vision correction centers.

Methods: This noncomparative case series reviewed the medical records of 12 patients (22 eyes) who had clinical features consistent with PDS at the time of the initial preoperative refractive evaluation and had LASIK surgery.

Results: Twenty eyes (90.9%) of 11 patients had an uneventful course after LASIK and a good final uncorrected visual acuity (mean follow-up 26 months). One patient (2 eyes) with PDS and suspicion of glaucoma on topical β-blocker therapy had delayed healing, fluctuations in vision, and a lengthy visual recovery.

Conclusions: Corneal findings of PDS do not appear to affect the intraoperative or postoperative outcomes of LASIK. However, patients who have PDS in the context of glaucoma and therapy with an intraocular-pressure-lowering agent may experience delayed healing and a less predictable visual outcome.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ Presented in part at the ASCRS Symposium on Cataract, IOL and Refractive Surgery, Philadelphia, Pennsylvania, USA, June 2002.

☆☆ None of the authors has a financial interest in any product mentioned.

PII: S0886-3350(03)00519-4

doi:10.1016/S0886-3350(03)00519-4

Journal of Cataract & Refractive Surgery
Volume 30, Issue 1 , Pages 110-114, January 2004

Article Tools